CSL Seqirus Canada is pleased to provide the following information for the upcoming season:
On March 7th, 2023, the World Health Organization (WHO) confirmed the strain recommendations for the 2023/2024 Northern Hemisphere season. For both egg-based quadrivalent and cell or recombinant-based quadrivalent vaccines, there is a change specific to the H1N1 strain from both NH22 and SH23 seasons. The remaining strains remain unchanged.
Egg-based quadrivalent vaccines:
- H1N1pdm: an A/Victoria/4897/2022-like virus (change from SH 2023 vaccine strain)
- H3N2: an A/Darwin/9/2021-like virus (no change from SH 2023 vaccine strain)
- B/Victoria: a B/Austria/1359417/2021-like virus (no change from NH 2022/23 vaccine strain)
- B/Yamagata: a B/Phuket/3073/2013-like virus (no change from NH 2022/23 vaccine strain)
Cell or recombinant-based quadrivalent vaccines:
- H1N1pdm: an A/Wisconsin/67/2022-like virus (change from SH 2023 vaccine strain)
- H3N2: an A/Darwin/6/2021-like virus (change from SH 2023 vaccine strain)
- B/Victoria: a B/Austria/1359417/2021-like virus (no change from NH 2022/23 vaccine strain)
- B/Yamagata: a B/Phuket/3073/2013-like virus (no change from NH 2022/23 vaccine strain)
If you wish to review the WHO recommendations, please click on the link: 2023-2024 WHO Strain Recommendation
CSL Seqirus is a central partner to clinicians and pharmacists, providing a range of vaccines to offer their patients and consumers innovative options.
'CSL Seqirus' work with leading Canadian researchers, healthcare professionals and public health leaders to advance scientific knowledge and global influenza research underscore our customer relationships.
National & Provincial Recommendations
NACI Seasonal Influenza Vaccine Statement
Please click on the links below to access additional customer information.